Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aurora Cannabis, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aurora Cannabis, Inc. ("Aurora" or the "Company") (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 inclusive (the "Class Period").

(PRNewsfoto/Glancy Prongay & Murray LLP)

If you suffered a loss on your Aurora investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/aurora-cannabis-inc/ . You can also contact Charles H. Linehan , of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com or visit our website at www.glancylaw.com to learn more about your rights.

On September 8, 2020 , the Company announced that it expected to record up to $1.8 billion in goodwill impairment charges in fourth quarter 2020. According to Aurora's press release, these charges included "up to $90 million " in fixed asset impairment charges "due to production facility rationalization, and a charge of approximately $140 million in the carrying value of certain inventory, predominantly trim, in order to align inventory on hand with near term expectations for demand."

On this news, the Company's stock price fell $0.99 per share, or more than 11%, to close at $7.52 per share on September 8, 2020 , thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on LinkedIn , Twitter , or Facebook .

If you purchased or otherwise acquired Aurora securities during the Class Period, you may move the Court no later than December 1 , 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com , or visit our website at www.glancylaw.com . If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/glancy-prongay--murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-aurora-cannabis-inc-acb-301173738.html

SOURCE Glancy Prongay & Murray LLP

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Trulieve to Open Florida Medical Cannabis Dispensaries in Madison and Panama City

Grand opening celebrations at both locations Friday, July 5 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of new medical cannabis dispensaries in Madison and Panama City, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cronos Brand Spinach® Celebrates Summer with New Launches

Cronos Group Inc.'s (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") Spinach ® brand is expanding its portfolio of award-winning and best-selling cannabis products just in time for the summer months. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach ® edibles and a premier milled flower product.

The new SOURZ by Spinach ® Fully Blasted gummies offer the same great-tasting SOURZ by Spinach ® flavors, now with 10 mg of THC per piece. The SOURZ by Spinach ® Tropical Party Pack introduces new gummies with bolder tropical flavors, in the distinctive Spinach ® "S" shape. These gummies have a perfect blend of sour and sweet and utilize Cronos' proprietary flavor-masking technology.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. Announces Results of 2024 Annual Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders held yesterday, June 20, 2024 (the "Meeting"), shareholders holding a total of 274,097,252 common shares of the Company voted in person or by proxy, representing 71.75% of the total number of common shares of the Company outstanding.

Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 26, 2024 was elected as a director of the Company, with each director receiving in excess of 93.4% of the votes cast in favor of his or her election. The detailed results of the vote for the election of directors are as follows:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Group Announces Expansion of GrowCo to Fuel Global Growth

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, announced an expansion of Cronos Growing Company ("GrowCo"). GrowCo is a leading cannabis cultivation company that Cronos owns 50% of. The investment will be funded by an additional credit facility provided by Cronos and is intended to assist GrowCo's expansion of its purpose-built cannabis facility to address the increased global market demand for high-quality cannabis flower.

Key Highlights of the Investment:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Goodness Growth Holdings Announces Closing of Recently Announced Non-Brokered Private Placement

Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that it completed the previously announced non-brokered private placement of its subordinate voting shares on June 14, 2024.

In aggregate, the Company issued 1,300,078 subordinate voting shares at a 30-day volume weighted average price (VWAP) of US $0.5384 as of May 17, 2024, representing gross proceeds of US $700,000. As previously disclosed, proceeds from the transaction will be utilized in connection with a mortgage note that's supporting the relocation of one of the Company's retail dispensaries in Minnesota.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cannabis plant.

What Would US Cannabis Rescheduling Mean for Stocks and Investors?

The US Drug Enforcement Administration (DEA) has initiated proceedings to reclassify cannabis from a Schedule I substance to a Schedule III substance, marking a significant step towards cannabis reform in the country.

After months of deliberation, the Associated Press reported on April 30 that the DEA would move to reclassify cannabis from Schedule I, a category it currently shares with heroin and methamphetamines, to Schedule III, which is reserved for substances with low potential for dependence and accepted medical use.

The move from the DEA comes almost a year after the Department of Health and Human Services (HHS) suggested that cannabis be reclassified on August 29, 2023. In December 2023, the DEA sent a letter to Congress in which it indicated its intent to review the evidence provided by the HHS. This was followed by months of evaluation and consideration by the DEA, as well as discussions and advocacy for cannabis reform by lawmakers and other stakeholders.

Keep reading...Show less

Latest Press Releases

Related News

×